Myasthenia gravis-Pathophysiology, diagnosis, and treatment.
Tannemaat MR, Huijbers MG, Verschuuren JJGM.
Handb Clin Neurol. 2024;200:283-305. doi: 10.1016/B978-0-12-823912-4.00026-8.
Pediatric Myasthenia Gravis.
Peragallo JH.
Semin Pediatr Neurol. 2017 May;24(2):116-121. doi: 10.1016/j.spen.2017.04.003. Epub 2017 Apr 7.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team.
Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7.
Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review.
Lindroos JLV, Bjørk MH, Gilhus NE.
J Clin Med. 2024 Feb 17;13(4):1136. doi: 10.3390/jcm13041136.
Myasthenia gravis.
Pasnoor M, Wolfe GI, Barohn RJ.
Handb Clin Neurol. 2024;203:185-203. doi: 10.1016/B978-0-323-90820-7.00006-9.
Novel Immunotherapies for Myasthenia Gravis.
Nair SS, Jacob S.
Immunotargets Ther. 2023 Apr 4;12:25-45. doi: 10.2147/ITT.S377056. eCollection 2023.
Guideline for the management of myasthenic syndromes.
Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, Hoffmann S, Hoffmann HS, Jander S, Keller C, Marx A, Melms A, Melzer N, Müller-Felber W, Pawlitzki M, Rückert JC, Schneider-Gold C, Schoser B, Schreiner B, Schroeter M, Schubert B, Sieb JP, Zimprich F, Meisel A.
Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023.
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment.
Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, Madsen S, Piehl F, Popperud TH, Punga AR, Schirakow L, Vissing J.
Eur J Neurol. 2024 May;31(5):e16229. doi: 10.1111/ene.16229. Epub 2024 Feb 6.
Current drug treatment of myasthenia gravis.
Vanoli F, Mantegazza R.
Curr Opin Neurol. 2023 Oct 1;36(5):410-415. doi: 10.1097/WCO.0000000000001196. Epub 2023 Aug 30.
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, De Bleecker JL, Murai H, Meisel A, Beydoun SR, Pasnoor M, Guglietta A, Van Hoorick B, Steeland S, T'joen C, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT+ Study Group.
Front Neurol. 2024 Jan 17;14:1284444. doi: 10.3389/fneur.2023.1284444. eCollection 2023.
